Associations between ultrasound screening findings and cholangiocarcinoma diagnosis in an at-risk population.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 08 2022
06 08 2022
Historique:
received:
05
05
2022
accepted:
31
07
2022
entrez:
6
8
2022
pubmed:
7
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
The rate of cholangiocarcinoma (CCA) is increasing every year, especially in northeastern Thailand. Screening for CCA using ultrasonography (US) is the fastest technique to identify patients in early stage of CCA development. Currently, few studies have examined patterns of hepatobiliary abnormalities identified using US, which can be indicative of CCA. We aim to evaluate the rate of CCA and its relations to history of US findings. Our study included participants who underwent US and pathological diagnosis of CCA from the Cholangiocarcinoma Screening and Care Program, Northeast Thailand between 2013 and 2020. Data on histological findings were based on the standard protocol of the tertiary hospital at Khon Kaen University. CCA data is categorized into two groups (yes/no) to find the relationship with history of US findings. The adjusted odds ratio (AOR) and their 95% confidence intervals (CI) were used to evaluate the relationship obtained by multiple logistic regression. Of 1880 subjects who underwent US and a pathological diagnosis of CCA, the overall rate of CCA was 35.74%. CCA rate among those with liver mass (LM) was 54.85% and with dilated bile duct (DBD) was 62.01%. The relationship between DBD and CCA was highly significant (AOR = 3.46; 95% CI 2.74-4.36) followed by LM (AOR = 2.28; 95% CI 1.81-2.86) P value < 0.001. Our study reveals that US findings history have a strong association with CCA, especially in people diagnosed with DBD and LM. Therefore, these abnormalities can be indicators for suspected CCA diagnosis through US.
Identifiants
pubmed: 35933509
doi: 10.1038/s41598-022-17794-9
pii: 10.1038/s41598-022-17794-9
pmc: PMC9357059
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13513Informations de copyright
© 2022. The Author(s).
Références
Sci Rep. 2020 Oct 8;10(1):16855
pubmed: 33033306
Radiology. 1989 Sep;172(3):689-92
pubmed: 2549565
Gastroenterology. 2005 Mar;128(3):620-6
pubmed: 15765398
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):605-614
pubmed: 29579789
BMJ Open. 2019 Mar 20;9(3):e023217
pubmed: 30898798
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
J Med Assoc Thai. 2014 Apr;97(4):415-22
pubmed: 24964684
Visc Med. 2016 Dec;32(6):395-400
pubmed: 28229073
Korean J Radiol. 2011 May-Jun;12(3):269-79
pubmed: 21603286
HPB (Oxford). 2020 Jun;22(6):874-883
pubmed: 31662222
Curr Opin Gastroenterol. 2008 May;24(3):349-56
pubmed: 18408464
Liver Int. 2010 Feb;30(2):215-21
pubmed: 19840244
PLoS Negl Trop Dis. 2021 Sep 20;15(9):e0009741
pubmed: 34543283
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8
pubmed: 17689296
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
Proc (Bayl Univ Med Cent). 2021 Jun 10;34(6):693-695
pubmed: 34732990
United European Gastroenterol J. 2021 Dec;9(10):1128-1135
pubmed: 34533900
J Hepatobiliary Pancreat Sci. 2014 May;21(5):316-22
pubmed: 24420706
Sci Rep. 2019 Oct 3;9(1):14263
pubmed: 31582774
Am J Gastroenterol. 2007 May;102(5):1016-21
pubmed: 17324130
Eur J Gastroenterol Hepatol. 2022 Mar 1;34(3):338-344
pubmed: 34775457
Ann Hepatol. 2017 Aug 1;16(4):565-568
pubmed: 28611259
Cancer. 2020 Jun 1;126(11):2666-2678
pubmed: 32129902
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Liver Int. 2015 Mar;35(3):1048-53
pubmed: 24923595
J Hepatol. 2020 Jan;72(1):95-103
pubmed: 31536748
BMC Cancer. 2015 Jun 09;15:459
pubmed: 26054405
BMC Cancer. 2016 Jun 02;16:346
pubmed: 27251649
World J Gastroenterol. 2017 Oct 21;23(39):7160-7167
pubmed: 29093624